Skip to content

Author

A. Menozzi

We have 3 of 111 papers

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Open access Oct 2026

Ticagrelor Monotherapy or Aspirin Plus Prasugrel After Percutaneous Coronary Intervention

Background The 2025 American College of Cardiology/American Heart Association guidelines endorse de-escalation to ticagrelor monotherapy after percutaneous coronary intervention (PCI) for acute coronary syndromes (ACSs), whereas the 2023 European Society of Cardiology guidelines recommend 12-month dual antiplatelet the...

Michele Maremmani, Enrico Citerni, O. de Filippo et al. · 0 citations
Aug 2026

Cangrelor in elderly patients undergoing percutaneous coronary intervention: findings from the ICARUS Registry.

Elderly patients were at higher risk of NACE, driven by an increased risk of both ischemic and bleeding events, the latter including access-site and nonaccess-site hemorrhages of both minor and major severity.

S. Benenati, F. Gragnano, Sebastiano Stratoti et al. · 1 citation
Open access Aug 2026

LDL Cholesterol Lowering With Evolocumab Before Percutaneous Coronary Intervention for Acute Myocardial Infarction: The AMUNDSEN Randomized Clinical Trial.

In patients with acute MI undergoing PCI, first-line evolocumab combined with high-intensity lipid-lowering therapy produced rapid and sustained LDL-C reduction, with more than 80% of patients reaching the guideline-recommended target at 1 year.

G. Montalescot, E. Ferrari, G. Souteyrand et al. · 3 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.